OncoDaily Pulse

Aug 24, 2025, 11:24

Yousef Zakharia: Meet the Experts of VIRO 2025

The Global Voices in Renal Oncology (VIRO) Virtual Congress, organized by OncoDaily, will be held on September 11–12, 2025. Chaired by Dr. Rana R. McKay with co-chair Dr. Yüksel Ürün, this year’s program will feature around 50 leading experts in renal oncology from across the globe, sharing cutting-edge updates and future perspectives.

The congress is free to attend.
Register here: https://forms.gle/qcQyaGMQfHDhanfD9

Co-Chair of VIRO

Images Name

Rana McKay
Professor of Medicine and Urology at UC San Diego Health Co-leader of the GU Oncology Program at Moores Cancer Center

As Co-Chair of VIRO, Dr. Rana McKay (University of California, San Diego) opened the congress with her talk on
“Future Directions: Emerging Agents and Combinations.”

She emphasized the momentum in renal cell carcinoma (RCC) research, highlighting how novel immunotherapies, targeted drugs, and rational combination strategies are reshaping patient care. Dr. McKay underscored the importance of personalized, biomarker-driven approaches and global collaboration, aiming to optimize survival and quality of life worldwide.

Spotlight on Yousef Zakharia

Dr. Yousef Zakharia is a Medical Oncologist and Vice-Chair of the Genitourinary Malignancy Disease Group at the Mayo Clinic Comprehensive Cancer Center. He is internationally recognized for his leadership in multidisciplinary approaches to advanced renal cell carcinoma (RCC) and his expertise in integrating systemic and local therapies to optimize patient outcomes.

At the Global Voices in Renal Oncology (VIRO) Virtual Congress 2025, Dr. Zakharia will participate in the Case-Based Discussion: “Delayed CRN and Consolidative SBRT, Multidisciplinary Integration in Advanced RCC”. His session will provide an in-depth look at how timing, coordination, and treatment sequencing can influence outcomes in patients with advanced disease.

Dr. Zakharia will discuss

Clinical considerations in delayed cytoreductive nephrectomy (CRN).
The role of consolidative stereotactic body radiotherapy (SBRT) in metastatic RCC.
Multidisciplinary strategies to integrate systemic therapy with local interventions.
Case-based examples highlighting individualized treatment decision-making.

Through his focus on delayed CRN and consolidative SBRT, Dr. Zakharia underscores the importance of collaborative, evidence-driven care. His expertise reflects the evolving landscape of advanced RCC management, where multidisciplinary integration aims to improve survival and quality of life for patients.